Osteoporosis as a primary health concern

International Conference on Osteoporosis, Arthritis and Musculoskeletal Disorders

Pulsus Group Inc is a Medical publisher that adheres to stringent peer-review procedure with a view to set an example in promoting standard medical research with integrity. Pulsus Group takes pride in getting the endorsements of prestigious associations and societies like Canadian medical societies.  As an ardent supporter of medical publishing, Pulsus Group closely associates with the Canadian and other international medical research associations. It publishes a wide range of medical journals that focus on medical specialties like cardiology, Integrative Medicine, Surgery and Reproductive Medicine.Pulsus group is closely associated with globally renowned academic and research societies like Canadian Society of Plastic Surgeons, Canadian Society for Aesthetic Plastic Surgery, Groupe pour l'Avancementde la Microchirurgie Canada, Canadian Society for Surgery of the Hand.

Pulsus invites you to attend “International Conference on Osteoporosis, Arthritis and Musculoskeletal Disorders ” that is to be held during September 21-22, 2017 at Madrid, Spain providing an international platform for physicians, rheumatologists, young researchers, students, physiatrists, orthopedists, and geriatricians to share the information and scientific progress in treating osteoporosis and musculoskeletal disorders.

This conference concentrates on the newest and advanced innovations in all the areas of osteoporosis and arthritis research. This conference highlights the theme, “Osteoporosis and Musculoskeletal Disorders as primary health concern” that emphasizes on quality health of the world population. The conference includes workshops, symposiums, special keynote sessions conducted by eminent and notable speakers who surpass in the field of orthopaedics that include the topics Osteoporosis, Osteoarthritis, Rheumatoid Arthritis, Musculoskeletal Disorders, Prevalence and Risk Factors, Pharmacological Treatment, Alternative Treatments, Nutrition and Prevention. This International Conference additionally encourages the active participation of young student researchers since we are hosting Poster Award Competition and Young research Forum at the conference venue.

Why to attend:

Medical doctors, patients and health care providers contemplate the hindrance of orthopedic diseases as a vital tool to enhance the overall health status of the population. Worldwide, osteoporosis causes over 8.9 million fractures annually, leading to an osteoporotic fracture every three seconds. Musculoskeletal conditions have a significant impact on society due to their incidence, severity, and resultant incapacity.

Osteoporosis is estimated to have an effect on two hundred million women worldwide - about ten percent of women aged sixty, twenty percent of women aged seventy, forty percent of women aged eighty and thirty three percent of women aged ninety. It is estimated that the residual lifetime risk of experiencing an osteoporotic fracture in men over the age of fifty is up to twenty seven. Osteoarthritis is irreversible, thereby difficult to cure. The genetic contribution to susceptibility of rheumatoid arthritis is estimated to be 60%. Recognizing the importance of this issue, Pulsus group is set to arrange a conference on osteoporosis and musculoskeletal disorders during September 28-29, 2017 at Madrid, Spain planning to increase awareness of the diseases with relation to current standing and future burden of the diseases on world population. This conference additionally provides a worldwide platform for physicians, rheumatologists, young researchers, students, physiatrists, orthopedists, and geriatricians to share the information and scientific progress in treatments.

Target Audience:

o   Osteology Students and Scientists

o   Osteoporosis Researchers

o   Pediatricians

o   Orthopedists

o   Osteology Faculty

o   Rheumatologists

o   Diagnostic Radiologists

o   Physiotherapists

o   Medical Colleges

o   Orthopedic Associations and Societies

o   Business Entrepreneurs

o   Nurse practitioners

o   Manufacturing Medical Devices Companies

o  Endocrinologists

o   Prosthetists and orthotists

Madrid, Spain

September 21-22, 2017

Register for the Conference

Conference News


Track 1: Osteoporosis and geriatrics

Osteoporosis is a decrease in the density of bone, decreasing its strength and leading to fragile bones. Most cases occur in postmenopausal women and older men. Gonadal insufficiency is a very important factor in both men and women. Symptoms are fractures of the spine, wrist or hip, Backache, a gradual loss of height and an accompanying stooped posture. Hormonal factors considerably determine the pace of bone resorption; lack of estrogen as a result of menopause will increase bone resorption, also as decreasing the deposition of new bone that takes place in weight-bearing bones.

Track 2: Osteoporosis Endocrinology

Hormonal factors considerably determine the pace of bone resorption; lack of oestrogen as a result of menopause will increase bone resorption, also as decreasing the deposition of new bone. Endocrinology is an important aspect of osteoporosis. Calcium metabolism additionally plays a major role in bone turnover, and deficiency of calcium and vitamin d ends up in impaired bone deposition; additionally, the parathyroid glands react to low calcium levels by secreting parathyroid hormone (parathormone, PTH), that will increase bone resorption to make sure ample calcium in the blood.

Track 3: Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune disorder which mainly affects joints. The typical symptoms are warm, swollen, and painful joints. Pain and stiffness progresses and becomes worse when treated. The wrist and hands are most commonly affected. The disease may also affect other parts of the body. This may result in complications like low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy are also the symptoms of rheumatoid arthritis.

Track 4: Osteoarthritis

Osteoarthritis is a joint disease caused due to breakdown of joint cartilage and the underlying bone. Causes are abnormal joint or limb development, previous joint injury, and genetic factors. Risk is high in overweight people, those who have one leg of a different length, and have jobs that lead to high levels of joint stress. The symptoms include pain in the affected area, resulting in decreased ability to move and stiffness, occasional effusion, tenderness, crepitus. Commonly affected areas are hands, spine, and knees.

Track 5: Other Musculoskeletal Disorders

Musculoskeletal disorders are the ones that affect muscles, bones and related nerves. Some of the common disorders are epicondylitis, carpal tunnel syndrome, back pain, tendinitis, tension neck syndrome, fibromyalgia etc. The severity of each disorder varies in terms of pain and disability. Most of these conditions may be caused due to mechanical stress and common wear and tear. Some disorders maybe of genetic origin. These disorders drastically affect the everyday life due to decrease in motion, fatigue and pain.

Track 6: Consequences of Musculoskeletal disorders

The major consequences of musculoskeletal disorders are decreased movement and disability which leads to inability to work and perform other physical activities. This may also lead to psychological stress on the affected patients leading to depression. Musculoskeletal disorders are a huge burden on individuals, social care systems and health systems, with indirect costs being very high. Increased risk of mortality is seen in severe osteoporosis and arthritis. Economic burden on patients affected with musculoskeletal disorders progresses with time and treatment.

Track 7: Advancements in Diagnostic Tools

Based on the symptoms and severity diagnosis of musculoskeletal disorder can be done, however, in certain cases it is difficult to differentiate. The most common tool for diagnosis of most of the musculoskeletal disorders is the x-ray as in case of osteoarthritis. Dual-energy X-ray absorptiometry scan (DXA) can be used for the diagnosis of osteoporosis. Other diagnosis tools include MRI, Ultrasound and certain tests like blood tests and urine tests.  Rheumatoid arthritis is diagnosed by an elevated erythrocyte sedimentation rate or C-reactive protein, which may indicate the presence of an inflammatory process in the body. Other common blood tests look for rheumatoid factor and anti-cyclic citrullinated peptide antibodies. Chemical biomarkers are very useful tools in detecting bone degradation.

Track 8: Novel Pharmacological Treatments

Treatment of osteoporosis is achieved by using SERMS most commonly. Strontium ranelete and hormonal replacement therapy in post-menopausal women shows effective treatment of osteoporosis. Treatment for pain in osteoarthritis is done using acetaminophen primarily. NSAIDS and opioids may also be used for treatment of osteoarthritis and most of the musculoskeletal disorders including rheumatoid arthritis. Disease-modifying antirheumatic drugs can slow the progression of rheumatoid arthritis which includes methotrexate, leflunomide, hydroxychloroquine and sulfasalazine.

Track 9: Orthopedic Surgeries

Kyphoplasty and vertebroplasty are the common surgical procedures in case of spinal fractures in osteoporosis. Vesselplasty is a surgical alternative in the treatment of vertebral compression fractures which is minimally invasive.  Arthroscopy is performed in case of arthritis to examine and repair a joint. An osteotomy may relieve symptoms of osteoarthritis, but knee replacement surgery eventually is needed in case of severe osteoarthritis. Other surgical procedures for arthritis include Synovectomy, Tendon repair, and Joint fusion.

Track 10: Musculoskeletal regenerative medicine

Regenerative medicine is the branch of medicine that deals with the use of therapeutic stem cells, tissue engineering for regenerating human cells and production of artificial organs. Several of the regenerative medicine products currently available in the market are for musculoskeletal disorders. Mesenchymal precursor cell (MPC), Mesenchymal Stem cells, autologous engineered neocartilage is some of the commonly used techniques. Intense research is in progress globally for the different possibilities of regenerative medicine in musculoskeletal regeneration

Track 11: Alternative Treatments

Exercise is a critical part of strengthening bone mass and recommends eating plenty of calcium-rich foods, such as nonfat milk, low-fat yogurt, broccoli, cauliflower, salmon, tofu, and leafy green vegetables. Acupuncture and Tai Chi are also used for Osteoporosis and osteoarthritis. While more scientific research is needed on the subject, some herbs and supplements are believed to reduce or potentially stop bone loss caused by osteoporosis. There are numerous benefits to using physiotherapy as a method for treating patients with osteoporosis and other musculoskeletal disorders.

Track 12: Nutrition and Prevention

Nutrition is the most important criteria for general health and prevention of diseases. Food rich in calcium and vitamin D like milk, yogurt, fish etc. prevent osteoporosis. Fish and other food with omega-3 fatty acids are beneficial for joints. Consumption of required amount of water daily is necessary as water lubricates the joints.  Daily intake of fruits and vegetables with various benefits is necessary for bone health. Fruits rich in Vitamin C and Vitamin A are good for joints. Vitamin C may slow the wear and tear on your joints by playing a key role in the formation of collagen, which is a key component of cartilage and bone. Antioxidants which help fight free radicals are necessary for general health.

Track 13: Supportive Approaches

An orthosis is an externally applied device which is used to modify the structural and functional characteristics of the neuromuscular and skeletal system which are used in supportive treatment of osteoporosis. In patients with osteoarthritis of the knee and hip Moderate exercise is beneficial with respect to pain and function. Knee braces and prosthetics maybe uses for relieving the pain by decreasing the stress on joints. Supplements with necessary vitamins can be useful for supportive treatment in musculoskeletal disorders. Calcium and Vitamin D supplements are recommended in osteoporosis to improve bone density. Glucosamine and SAMe have research background for maintaining joints.


Market Analysis

The organizing committee of International Conference on Osteoporosis, Arthritis and Musculoskeletal Disorders-2017   is preparing for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the International Conference on Osteoporosis, Arthritis and Musculoskeletal Disorders -2017, where you can have a present outlook of osteoporosis and its market.

Importance and scope:

Medical doctors, patients and health care providers consider the prevention of orthopedic diseases as an essential tool to improve the general health status of the population. Worldwide, osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds Osteoporosis is estimated to affect 200 million women worldwide .Increase in osteoporosis cases results in a decline in economy with respect to health. Hence it is necessary to start a global initiative for awareness, prevention and effective treatment of osteoporosis.

International Conference on Osteoporosis, Arthritis and Musculoskeletal Disorders-2017 aims at gathering physicians,  rheumatologists, young researchers, students, physiatrists, orthopedists, and geriatricians at global platform to present their respective views and research regarding osteoporosis and share knowledge about osteoporosis for betterment of both academia and business.

Why Spain?

In 2010 approximately 204,000 new fragility fractures reported in Spain. The economic burden of new and prior fractures € 2,842 million each year; by 2025 burden will increase by 30 % to € 3.68 billion. Bone mineral density measurement is underutilized in majority of European countries due to limited availability of densitometers, restrictions in personnel permitted to perform scans, low awareness of usefulness of BMD testing, limited or nonexistent reimbursement.

In Spain there was a 54% increase in new cases of hip fracture within a 14-year period (1998-2002). This increase occurred mainly in women (64%) compared to men (19%).Spain: 13% of patients who have suffered a fracture die after 3 months and this figure rises to 38% after 24 months. Furthermore, after experiencing a vertebral fracture, 45% of patients suffer from functional damage and 50% are afflicted by partial or total disability in Spain. Average total annual costs for arthritis were euro1500 per patient. Direct costs accounted for 86% of the total cost. Estimated national cost was 4740 million euros, which was about 0.5% of the gross national product.

Long-term disability costs were estimated around € 51,786 with the simulated number of individuals with prior fractures that had been transferred to nursing homes due to the fracture.  Patients on treatment made an annual physician visit costing € 109 and a DXA scan costing € 79 every second year to monitor treatment. The cost of osteoporosis in 2010 was estimated at € 2,842 million. First year costs, subsequent year costs and pharmacological fracture prevention costs amounted to € 1,372 million, € 1,055 million and € 414 respectively.

number of deaths in Spain after first year of fracture

Estimated number of women and men with osteoporosis in Spain in the year 2010

number of research papers in Spain and ranking


List of major companies producing drugs for osteoporosis treatment:-

  • ·         Merck
  • ·         Novartis
  • ·         Sunofi
  • ·         Eli lilly and company
  • ·        Amgen

Sales of osteoporosis drugs by leading pharmaceutical companies

Key vendors in the market for pain medications  are -

  • Abbott Laboratories
  • Johnson & Johnson
  • Novartis
  • Pfizer

List of some important osteoporosis associations in Spain and world


Present and future scenario:

There were an estimated 9.0 million osteoporotic fractures in the year 2000 of which 1.6 million were hip fractures, 1.7 million forearm fractures and 1.4 million were clinical vertebral fractures. High number of osteoporotic fractures occurred in Europe (34.8%). Present survey depicts that Osteoporosis is estimated to affect 200 million women worldwide. About 1/10 of women aged 60, 1/5 of women aged 70, 2/5 of women aged 80 and 2/3 of women aged 90. Approximately twenty two million women and five and a half million men in the European Union had osteoporosis in 2010. In the United States about 8 million women and one to 2 million men had osteoporosis in 2010. This causes a large economic burden on the healthcare system due to costs of treatment, long-term disability, and loss of productivity in the working population. The European Union spends thirty seven billion euros per year in healthcare costs related to osteoporosis, and the USA spends an estimated nineteen billion US dollars annually for related healthcare costs. The prevalence of osteoporosis and osteoarthritis is continuing to escalate with the increasingly elderly population. The major complication of osteoporosis is an increase in fragility fractures leading to morbidity, mortality, and decreased quality of life. In the European Union, the number of osteoporotic fractures was estimated at 3.79 million in 2000. A baseline fracture is a very strong predictor of further fractures with twenty percent of patients experiencing a second fracture within the first year. Osteoporosis Drugs Market might reach 8.9 billion US dollars in 2020 due to High Incidence of Osteoporosis. The costs to health care services are already considerable and, on current trends, are predicted to double by 2050. The burden of rheumatoid arthritis which is incurable autoimmune disorder increases with age and progression of disease. It’s estimated to have an effect on about 4.9 million people across the key markets. It is expensive to health care services and results in substantial economic and quality of life impairments for patients, at least 500th of who are unable to keep up full-time employment inside ten years of onset. Rheumatoid arthritis drug market will experience slight growth over 10 years as sales increase from $11.1 billion in 2011 to $15.2 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. It is predicted that the global osteoarthritis pain drugs market to grow at a CAGR of more than 8% by 2020. There are significant unmet medical needs in this market due to the chronic nature of osteoarthritis and the absence of effective curative therapies.  

estimated number of hip fractures in various regions predicted til 2050